Screener / SEC EDGAR /CIK 0001711279 /10-K filed Feb 17, 2026, compared with Feb 19, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Krystal Biotech, Inc. KRYS

Compare with peers Embed
SEC comment letters, last 20 years

2 reviews of KRYS's filings by SEC staff

UPLOAD and CORRESP
Reviews 2 latest letter Mar 30, 2023
Questions asked 11 each answered in the company's own letter
No closing letter 1 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 3 UPLOAD
  2. 2. Questions in them 11 numbered comments
  3. 3. Company replies 6 CORRESP
  4. 4. Reviews closed 1 of 2 closing letter

Half the closed reviews took 25 days or less from the first letter to the closing letter.

Form 10-K for the Fiscal Year Ended December 31, 2022

2023-03-30 to 2023-04-24 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2023-04-24
Research and Development Expenses, page 60
SEC asked
Given the importance of research and development expenses to your business model and the multiple product candidates under development, please revise future filings to disclose total costs by product candidate as well as by the nature of expense for each period presented. To the extent that you do not track expenses by product candidate, please disclose as such.
KRYS answered
to the Staff’s comment, the Company proposes to add in its future filings, beginning with the Form 10-Q for the quarter ended March 31, 2023, disclosure consistent with the proposed disclosure set forth on Annex A to this letter for as long as research and development expenses continue to represent a significant portion of the Company’s total expenses.
Rest of the answer

The Company anticipates that the proposed disclosure would be included in Part I, Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations under the caption “Results of Operations—Three Months Ended March 31, 2023 and 2022—Research and Development Expenses.”

Read in the reply
In its next report

First report after the company's reply of Apr 11, 2023: 10-Q filed May 8, 2023 ↗, against the 10-Q filed Nov 7, 2022 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2023-04-24

Filing review

2017-08-11 to 2017-09-15 · 10 questions · 2 letters from the SEC, 5 from the company
No closing letter
Critical estimates
Prospectus Summary · Overview, page 1
SEC asked (1)
Please clarify the meaning of any significant scientific or technical terms the first time they are used in order to ensure that lay readers will understand the disclosure. For example, please briefly explain what you mean by “ichthyosis," "icthyosis vulgaris," "non-integrating nature," and "skin tropism resulting in high transduction efficiencies." Please also explain how existing regulatory precedent and stability
Rest of the question

are considered strengths of your gene therapy platform.

KRYS answered
to

Comment 1:

In response to the Staff’s comments concerning the descriptions of “ichthyosis,” “ichthyosis vulgaris,” “non-integrating nature,” and “skin tropism,” the Company has revised the disclosure on pages 1, 2, 68, 71, 72 and 83 of the Public Filing. In addition, the Company has clarified in its disclosure on pages 2, 3, 72 and 73 of its Public Filing how existing regulatory precedent supports the use of an HSV-1 backbone in chronic gene therapy similar to the Company’s gene therapy platform, and the advantages that the viral stability of HSV-1 provides in terms of manufacturing,
Rest of the answer

storage, transportation and administration.

Read in the reply
Prospectus Summary · Overview, page 1
SEC asked (2)
We note your reference to key opinion leaders, including specific references to Dr. Peter Marinkovich and Dr. Andrew South. Please revise your disclosure to explain how often, and the manner in which, the KOLs are involved in your business. Please also clarify whether you compensate the KOLs.
KRYS answered
In response to the Staff’s comment, the Company has revised the disclosure on pages 2, 69 and 103 of the Public Filing to describe the nature of the KOLs’ involvement with the Company and have clarified the Company’s compensation arrangements with such KOLs. In addition, the Company has updated its discussion with respect to KOL’s on pages 2, 69 and 103 of the Public Filing to reflect an additional KOL, Dr.
Rest of the answer

John McGrath of King’s College London, with whom the

Company entered into a consulting agreement in July 2017 and whom assists the Company with the preclinical and clinical development of KB103 on an hourly basis.

Read in the reply
Risks Associated with our Business, page 3
SEC asked (3)
We note your disclosure that KB103 is based on novel technology. Please place your disclosure in appropriate context by disclosing that the U.S. Food and Drug Administration has not approved any human gene therapy product for marketing to date.
KRYS answered
In response to the Staff’s comment, the Company has revised the disclosure on pages 3, 4 and 68 of the Public Filing.
Read in the reply
Implications of Being an Emerging Growth Company, page 4
SEC asked (4)
Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.
KRYS answered
connection with this undertaking, the Company has provided as enclosures to a letter dated August 15, 2017 to the Staff (the “August 15 TTW Letter”), with copies of written communications, as defined in Rule

405 under the Securities Act, that have been presented to potential investors in reliance on Section 5(d) of the Securities Act, by the Company or anyone authorized to do so on its behalf.
Rest of the answer

The August 15 TTW Letter included two presentations that were prepared by the Company for use in meetings with potential investors on July 25, 2017, July 26, 2017, August 7, 2017, August 9, 2017, August 10, 2017 and August 16, 2017, in reliance on

Section 5(d) of the Securities Act. Such presentations were only made available for viewing by such investors during the Company’s presentations and no investors retained such information.

The Company advises the Staff that, since the August 15 TTW Letter and as of the date hereof, no other written communications, as defined in Rule 405 under the Securities Act, have been used in meetings with potential investors in reliance on Section 5(d) of the Securities Act.

Management’s Discussion and Analysis of Financial Condition and Operations Critical Accounting Policies and Significant Judgments and Estimates Stock

Read in the reply
Critical Accounting Policies and Significant Judgments and Estimates · Stock Based Compensation, page 55
SEC asked (5)
Once you have an estimated offering price or range, please explain to us how you determined the fair value of the common stock underlying your equity issuances and the reasons for any differences between the recent valuations of your common stock leading up to the IPO and the estimated offering price.
Rest of the question

This information will help facilitate our review of your accounting for equity issuances including stock compensation and beneficial conversion features.

KRYS answered
The Company respectfully acknowledges the Staff’s comment and confirms that it will provide an analysis explaining the reasons for the differences between recent valuations of its common stock leading up to the Company’s initial public offering and the estimated offering price once the Company has an estimated offering price range.
Read in the reply
Business · Our Lead Product Candidate: KB-103 for the treatment of DEB, page 77
SEC asked (6)
Please revise you disclosure under "Preclinical Proof of Concept for KB103" to indicate the dates on which you conducted the preclinical tests. Please also tell us whether the examples shown represent results that were achieved consistently in the preclinical tests. In the figures shown on page 76, please tell us how you measured the amount of COL7 expression and what you determined to be "high levels" of expression.
KRYS answered
In response to the Staff’s comment, the Company has revised the disclosure on page 76 of the Public Filing to indicate the dates on which the preclinical tests and animal studies for KB103 were conducted and to reflect that the results of such tests and studies were evaluated for consistency and reproducibility.
Rest of the answer

In addition, in response to the Staff’s comment, the Company has revised the disclosure on pages 76 and 77 (including Figure 4 therein) of the Public Filing to describe the Company’s method of measurement of the amount of COL7 expression and its determination as to the “high levels” of expression.

Read in the reply
Business · Our Lead Product Candidate: KB-103 for the treatment of DEB, page 77
SEC asked (7)
Please revise the charts on page 77 so that it is clear what information is presented and the significance of the different bars shown, including whether images are depicted or measured quantities. Please also revise the charts on pages 78 to 79 so that it is clear what information is represented by the lines extending from the bars shown, as they do not appear to align consistently with units shown.
KRYS answered
response to the Staff’s comment, the Company has revised the charts in Figure 8 and Figure 9 and their respective accompanying descriptions on page 79 of the Public Filing to clarify the information being presented, including that the images depicted are actual levels of LH3. The Company has also revised the charts in Figures 10, 11, 12 and 13 on pages 80, 81 and 82 of the Public Filing to remove the extraneous lines that previously extended from the bars shown.
Read in the reply
Business · Our Lead Product Candidate: KB-103 for the treatment of DEB, page 77
SEC asked (8)
Please explain the significance of KB103 infecting both keratinocytes and fibroblasts. General
KRYS answered
response to the Staff’s comment, the Company has revised the disclosure on pages 80 and 81 of the Public Filing to clarify the significance of KB103’s ability to transduce both keratinocytes and fibroblasts (which are cells that both produce COL7 in non-DEB afflicted skin) and thereby offer the potential to achieve therapeutic levels of COL7 following direct application to the skin, in contrast to most ex-vivo approaches which are only able to target either fibroblasts or keratinocytes due to limitations of their viral vector.
Rest of the answer

This supplements the disclosure on page 74 and 75 of the Public Filing, which describes the ability of KB103 to transduce both keratinocytes and fibroblasts to produce optimum therapeutic levels of secreted COL7 protein, which has been shown in clinical and non-clinical studies as necessary and sufficient to treat DEB in patients.

Read in the reply
Business · Our Lead Product Candidate: KB-103 for the treatment of DEB, page 77
SEC asked (9)
Please provide us proofs of all graphics, visual, or photographic information you will provide in the printed prospectus prior to its use, for example in a preliminary prospectus. Please note that we may have comments regarding this material.
KRYS answered
The Company acknowledges the Staff’s comment and respectfully advises the Staff that it does not currently intend to include any additional graphic, visual or photographic information in the printed prospectus. If, following the date of this letter, the Company determines to include additional graphic, visual or photographic information in the printed prospectus, it will provide proofs to the Staff prior to their use.

***

We hope that the foregoing has been response to the Staff’s comments and will provide you with marked copies of Amendment No. 1 to expedite your review.
Rest of the answer

If you have any questions about this letter or require any further information, please call John W. Campbell at (415) 268-7197.

Read in the reply
Critical Accounting Policies and Significant Judgments and Estimates · Stock Based Compensation, page 55
SEC asked
The number of shares underlying options granted in May and June 2017 and the weighted average exercise price per share of the June 2017 grants as presented in the table in your response letter do not agree to the table on page 56 of your Form S-1 filed August 21, 2017. Please tell us the reason for these discrepancies and revise your Form S-1 and/or cheap stock analysis accordingly.
KRYS answered
The Registration Statement reflected grants of 3,000 options in May 2017 and 7,211 options in June 2017. Upon further review, the Company determined that two awards totaling 3,000 options in the aggregate that were included in the 7,211 June option grant total, were approved by the Company’s Board of Directors in May at an exercise price of $11.07 per share. Following approval of the awards, the recipients of the awards delayed commencement of their employment until June.
Rest of the answer

The Company determined that these 3,000 share awards should properly be accounted for as a May 2017 grant, rather than a June 2017 grant, and this determination was reflected in the table and related discussion included in the

August 31 Letter. The table on page 60 of Amendment No. 1 has been revised to reflect the information provided in the August 31 Letter, as adjusted for a

4.5-to-1 stock split as described in Amendment No. 1.

The $27.71 weighted-average exercise price per share of the June 2017 grants as presented in the Registration Statement was calculated on the basis of 3,000 options granted at $11.07 per share and 4,211 options granted at $39.57 per share. The reclassification of the 3,000 share option awards from June 2017 to May 2017 resulted in the weighted-average exercise price of June grants being $39.57 per share, as presented in the August 31 Letter. The table on page

60 of Amendment No. 1 has been revised accordingly (as adjusted for a 4.5-to-1 stock split as described in Amendment No. 1).

In addition, we note for clarity that there was a scrivener’s error in a table presented in the August 31 Letter, where the weighted-average estimated fair value per share of common stock of the May 2017 grant was presented at $11.07 per share. This was a scrivener’s error and should have been $36.01 per share, as accurately reflected and discussed on page 7 of the same August 31 Letter. This number, as adjusted for the 4.5-to-1 stock split, appeared correctly on page 56 of the Registration Statement and also appears on page 60 of Amendment No. 1.

***

We hope that the foregoing has been response to the Staff’s comments and will provide you with marked copies of Amendment No. 1 to expedite your review. If you have any questions about this letter or require any further information, please call John W. Campbell at (415) 268-7197.

Read in the reply

Also in this review: company letter, Aug 31, 2017, company letter, Sep 15, 2017, company letter, Sep 15, 2017

Letters without questions

Other letters

UPLOAD and CORRESP
2 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 12 letters filed since 2017-08-11. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/KRYS/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.